Distinguished in Atypical Teratoid Rhabdoid Tumor (ATRT)

Dr. Michael Schulder

North Shore - Lij Medical PC
New Hyde Park, NY
Distinguished
in Atypical Teratoid Rhabdoid Tumor (ATRT)
Specialties:Neurosurgery
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Michael Schulder is a Neurosurgery provider in New Hyde Park, New York. Dr. Schulder and is rated as a Distinguished provider by MediFind in the treatment of Atypical Teratoid Rhabdoid Tumor (ATRT). His top areas of expertise are Astrocytoma, Oligodendroglioma, Schwannoma, Gamma Knife Radiosurgery, and Awake Craniotomy.

His clinical research consists of co-authoring 85 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurosurgery
Licenses
Neurological Surgery in NJ
Hospital Affiliations
Long Island Jewish Medical Center
North Shore University Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

NORTH SHORE - LIJ MEDICAL PC
450 Lakeville Rd, New Hyde Park, NY 11042
516-470-8445
Other Locations
NORTH SHORE - LIJ MEDICAL PC
300 Community Dr, Manhasset, NY 11030
NORTH SHORE - LIJ MEDICAL PC
350 Community Dr, Manhasset, NY 11030
516-562-3845
NORTH SHORE - LIJ MEDICAL PC
330 Community Dr, Manhasset, NY 11030
516-708-2550

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
Enrollment Status: Terminated
Publish Date: December 16, 2024
Intervention Type: Drug, Device, Radiation
Study Drugs: Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Bevacizumab, Carmustine
Study Phase: Phase 1/Phase 2
A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)
A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2024
Intervention Type: Radiation, Procedure, Drug
Study Drug: Temozolomide
Study Phase: Phase 3
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: May 31, 2024
Intervention Type: Combination product, Procedure, Drug
Study Drugs: IGV-001 Cell Immunotherapy, Temozolomide
Study Phase: Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
Phase I Study of Subventricular Zone Tumor Stem Cell Stereotactic Radiosurgery With Standard of Care Chemoradiation Therapy in Newly Diagnosed Malignant Gliomas (WHO III and WHO IV Astrocytomas)
Phase I Study of Subventricular Zone Tumor Stem Cell Stereotactic Radiosurgery With Standard of Care Chemoradiation Therapy in Newly Diagnosed Malignant Gliomas (WHO III and WHO IV Astrocytomas)
Enrollment Status: Withdrawn
Publish Date: March 15, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Enrollment Status: Terminated
Publish Date: July 22, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

85 Total Publications

Detecting and Addressing Secondary Neural Injuries in Cranial Surgery: Case Report.
Detecting and Addressing Secondary Neural Injuries in Cranial Surgery: Case Report.
Journal: The Neurodiagnostic journal
Published: August 20, 2024
Similar Doctors
Expertise in
21
conditions
Dr. Lyndon J. Kim
Neurosurgery | Oncology | Hematology Oncology
Expertise in
21
conditions
Dr. Lyndon J. Kim
Neurosurgery | Oncology | Hematology Oncology

Icahn School Of Medicine At Mount Sinai

1 Gustave Levy Place, Mount Sinai Emergency Room, 
New York, NY 
 (13.4 mi)
212-241-4572
Experience:
40+ years
Languages Spoken:
English
Offers Telehealth

Lyndon Kim is a Neurosurgery specialist and an Oncologist in New York, New York. Dr. Kim has been practicing medicine for over 40 years and is rated as an Elite provider by MediFind in the treatment of Atypical Teratoid Rhabdoid Tumor (ATRT). His top areas of expertise are Glioma, Astrocytoma, Glioblastoma, and Brain Tumor.

Expertise in
37
conditions
Dr. Jeffrey N. Bruce
Neurosurgery
Expertise in
37
conditions
Dr. Jeffrey N. Bruce
Neurosurgery

Trustees Of Columbia University In The City Of New York

622 W 168th St, 
New York, NY 
 (13.8 mi)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeffrey Bruce is a Neurosurgery provider in New York, New York. Dr. Bruce and is rated as an Elite provider by MediFind in the treatment of Atypical Teratoid Rhabdoid Tumor (ATRT). His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Gamma Knife Radiosurgery, and Awake Craniotomy.

Expertise in
31
conditions
Dr. Viviane S. Tabar
Neurosurgery
Expertise in
31
conditions
Dr. Viviane S. Tabar
Neurosurgery

Mskcc Surgery Group

1275 York Ave, 
New York, NY 
 (13.3 mi)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Viviane Tabar is a Neurosurgery provider in New York, New York. Dr. Tabar and is rated as an Elite provider by MediFind in the treatment of Atypical Teratoid Rhabdoid Tumor (ATRT). Her top areas of expertise are Astrocytoma, Brain Tumor, Glioma, Awake Craniotomy, and Gamma Knife Radiosurgery.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile